I-Mab Reports Acceptance Of IND Application In China For Phase 2 Trial With Enoblituzumab

I-Mab (IMAB) said the Center for Drug Evaluation of China National Medical Products Administration has accepted the company's IND application to initiate a phase 2 trial for enoblituzumab in combination with pembrolizumab in patients with selected solid tumors. The phase 2 trial will evaluate the efficacy of the combination of enoblituzumab and pembrolizumab.

I-Mab has in-licensed the rights to develop and commercialize enoblituzumab in Greater China from MacroGenics (MGNX).

Joan Shen, CEO of I-Mab, said: "We will be leveraging the data from clinical trials conducted by MacroGenics to advance the clinical development of enoblituzumab for approval in Greater China."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement. Specialized Bicycle Components, Inc. is recalling about 6,900 units of Tarmac SL7 Bicycles and Framesets for potential risk of fall and injury hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the bicycle's fork steerer tube can crack or break after harsh impact such as hitting a deep pothole or other stress event, posing fall and injury hazards.
Follow RTT